OncoSec Medical Inc (ONCSQ)

[hschlauch]

That is right, there is an unprecedented push to expand checkpoint inhibitor use. In fact, over two hundred combination trials to be exact, and every large pharma is getting into it. Merck isn't the only company with a good incentive to expand usage; it is practically every major biopharma company.

If a company is capable of improving TIL, specifically pd-1 and ctla-4 phenotypes, then they are setting the stage for improved responses in virtually every solid tumor indication.